Afatinib News and Research

RSS

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Novel drug combination overcomes resistance in aggressive KRAS-mutated lung cancer

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer.

13 Jan 2026

Whole-body imaging reveals where drugs bind at single-cell resolution

When you take a drug, where in your body does it actually go? For most medications, scientists can make only educated guesses about the answer to this question.

22 Dec 2025

Study reveals a unique vulnerability in melanoma patients with neurofibromin 1 mutations

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.

10 Jun 2025

AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic for Haiyitan® tablets (gumarontinib)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. today announced that the Japanese Ministry of Health, Labour and Welfare has approved the AmoyDx® Pan Lung Cancer PCR Panel

From Amoy Diagnostics 23 Aug 2024

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

26 Mar 2024

Novel drug combination shows promise in treating pancreatic cancer

Mutations in the KRAS gene are the major driver of pancreatic cancer. The resulting protein controls multiple signaling pathways involved in cell growth and survival. In cancer, the gene is mutated to be permanently "on," driving cells to excessively multiply and form tumors.

28 Jun 2023

Newly identified gene drives development of the second most common type of lung carcinoma

A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might someday be treated.

9 Jan 2023

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

Automated computational protocol identifies potential SARS-CoV-2 MPro inhibitor

As scientists race to discover new and effective antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many novel approaches are being utilized. Now, a new study published on the preprint bioRxiv in September 2020 reports on the discovery of a potentially beneficial enzyme blocker that could inhibit SARS-CoV-2 viral replication.

24 Sep 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020

Gero uses AI platform to identify potential anti-COVID-19 drugs

Gero, the leader in AI-driven drug discovery, has used its AI platform to identify the potential anti-COVID-19 drugs. Six of them have been approved, three were withdrawn, and the other nine have been already tested in clinical trials for other indications.

25 Mar 2020

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.

20 Aug 2019

Blood-based liquid biopsies can accurately track cancer treatment responses

Results of two clinical studies have added to evidence that blood-based liquid biopsies can accurately track lung cancer treatment responses by measuring circulating tumor DNA (ctDNA) during immunotherapy and related treatments.

14 Feb 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019

Scientists discover genetic causes underlying group of related infant cancers

The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators.

18 Jun 2018

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research.

16 May 2018

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC).

5 Jun 2017

Penn studies provide new understanding of lung cancer progression and prevention

Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

16 Mar 2017